Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: A multinational randomise phase III study

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 116-122

  Mattson, K V ^a   Abratt, R P ^b   ten Velde, G ^c   Krofta, K ^d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Docetaxel (Taxotere ); Induction; Neoadjuvant; Non small cell lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; LOMUSTINE; VINBLASTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; POSTOPERATIVE PERIOD; SAFETY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0037245967     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg009     Document Type: Article

References (41)

1. Goldberg M, Burkes RL. Induction chemotherapy for stage IIIA unresectable non-small cell lung cancer: the Toronto experience and an overview. Semin Surg Oncol 1993; 9: 108-113.
2. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940-945.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
4. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158.
5. Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7-14.
6. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.
7. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
8. Shepherd FA, Johnston MR, Payne D et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 1998; 78: 683-685.
9. Rosell R, Font A, Pifarre A et al. The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996; 109 (Suppl 5): 102S-106S.
10. Tonato M. The role of neoadjuvant chemotherapy in NSCLC. Chest 1996; 109 (Suppl 5): 93S-95S.
11. Pastorino U. Benefits of neoadjuvant chemotherapy in NSCLC. Chest 1996; 109 (Suppl 5): 96S-101S.
12. Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384-387.
13. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000; 18: 2354-2362.
14. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-1237.
15. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-972.
16. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13: 645-651.
17. Gandara DR, Vokes E, Green M et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18: 131-135.
18. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
19. Belani CP. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Semin Oncol 1999; 26 (Suppl 10): 15-18.
20. Belani CP, Einzig A, Bonomi P et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000; 11: 673-678.
21. Miller VA, Krug, LM, Ng KK et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 1346-1350.
22. Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 750-758.
23. Ornstein DL, Nervi AM, Rigas JR. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. Ann Oncol 1999; 10 (Suppl 5): S35-S40.
24. Dancey J, Shepherd F, Ramlau R et al. Quality of life (QOL) assessment in a randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 1999; 18: 491a (Abstr 1896).
25. Miller VA, Fossella FV, DeVore R et al. Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy. Proc Am Soc Clin Oncol 1999; 18: 491a (Abstr 1895).
26. Roszkowski K, Pluzanska A, Krzakowski M et al. Multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-157.
27. Lokich J, Anderson N. Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 1998; 9: 573.
28. Moon C, Verschraegen CF, Bevers M et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000; 11: 565-568.
29. Mattson KV, ten Velde G, Krofta K et al. Taxotere as neoadjuvant therapy for radically treatable stage III NSCLC. Preliminary results of an international phase III study. Proc Am Soc Clin Oncol 2000; 19: 483a (Abstr 1890).
30. Mattson K, Abratt R, ten Velde G et al. Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study. Lung Cancer 2001; 34 (Suppl 4): 21-23.
31. Moussa MA. Planning the size of survival time clinical trials with allowance for stratification. Stat Med 1988; 7: 559-569.
32. Amat S, Bougnoux P, Penault-Llorca F et al. Primary chemotherapy for operable breast cancer: high pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol 2000; 19: 128a (Abstr 500).
33. Gradishar WJ, Loh K, Erban J et al. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 1997; 11 (Suppl 8): 15-18.
34. Hutcheon AW, Ogston KN, Heys SD et al. Primary chemotherapy in the treatment of breast cancer: significantly enhanced clinical and pathological response with docetaxel. Proc Am Soc Clin Oncol 2000; 19: 83a (Abstr 317).
35. Komaki R, Scott CB, Sause WT et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1997; 39: 537-544.
36. Sause W, Kolesar P, Taylor S et al. A. Five-year results; phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992. Proc Am Soc Clin Oncol 1998; 17: 453a (Abstr 1743).
37. Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
38. Griesinger F, Baum RP, Paul J et al. Correlation of metabolic and morphometric tumor response after induction chemotherapy with docetaxel (D) and carboplatin (C) in stage III NSCLC. Proc Am Soc Clin Oncol 2000; 19: 548a (Abstr 2160).
39. Betticher DC, Hsu Schmitz SF, Gauthier Y et al. Neoadjuvant chemotherapy with docetaxel (DOC, Taxotere) and cisplatin (CIS) in patients (pts) with non-small cell lung cancer (NSCLC), Stage IIIA, N2 is highly active with few toxicities. Proc Am Soc Clin Oncol 1999; 18: 473a (Abstr 1824).
40. Katakami N, Okazaki M, Nishimura T et al. Phase II trial of induction carboplatin (CAR) and docetaxel (DOC) with concurrent radiation (RT) in early-stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19: 524a (Abstr 2060).
41. Nishimura T, Ikeda A, Katakami N et al. Phase II study of induction carboplatin (CAR) and docetaxel (DOC) with concurrent thoracic radiation (CTRT) followed by surgical resection in stage IB, IIA and IIB non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 254b (Abstr 2767).